IGF1 and acromegaly: In the recent phase II study, patients with acromegaly who were partial responders (IGF-I 1.0 – 2.5 x upper limit of normal) to monotherapy with iSRL when switched to once-daily paltusotine maintained control of IGF-I within 20% of baseline or lower in 87% after 13 weeks.